Electronic Supplementary Material (ESI) for Journal of Materials Chemistry B. This journal is © The Royal Society of Chemistry 2022

Supplementary Information

Construction of GSH-triggered cationic fluoropolymer as two-in-

one nanoplatform for combined chemo/gene therapy

Yu-Rong Zhan,^a Juan Tan,^b Meng-Wei Hei,^a Shi-Yong Zhang ^b Ji Zhang,^{*,a} and Xiao-Qi Yu^{*a,c} ^a Key Laboratory of Green Chemistry and Technology (Ministry of Education), College of Chemistry, Sichuan University, Chengdu 610064, P. R. China

^b College of Chemistry and National Engineering Research Center for Biomaterials, Sichuan University, Chengdu, 610064, China

° Department of Chemistry, Xihua University, Chengdu 610039, P. R. China

*Corresponding authors: jzhang@scu.edu.cn, +86-28-85412627 (J. Zhang); xqyu@scu.edu.cn, +86-28-85415886 (X.-Q. Yu).

	w/w=10	w/w=15	w/w=20	w/w=25
HeLa	1.58	5.35	9.93	14.11
U2OS	5.51	3.91	3.32	2.67

Table S1. Relative transfection efficiency of **PSSF** (according to PEI 25k) at various mass ratios (with reference to Figure 4C).



Figure S1. ¹H NMR spectrum of compound 2 in CDCl₃.



Figure S2. ¹³C NMR spectrum of compound 2 in CDCl₃.



Figure S3. ¹H NMR spectrum of compound SS in CDCl₃.



Figure S4. ¹³C NMR spectrum of compound SS in CDCl₃.



Figure S5. ¹H NMR spectrum of PSS in D₂O.



Figure S6. ¹H NMR spectrum of PSSF in D₂O.



Figure S7. ¹⁹F NMR spectrum of PSSF in MeOD.



Figure S8. (a)The fluorescence spectrum of DOX and DOX@PSSF at different concentrations. (b) Standard curve of FI_{600} -DOX concentration.



Figure S9. Particle size (columns) and zeta potential (dots) of PSSF and DOX@PSSF.



Figure S10. Cell viability after treatment with different **PSSF** concentrations for 48 h in 7702(A) and DC(B) cells



Figure S11. Hemolysis rate of PSSF at different concentrations after incubation with red blood for 2 h. Data represent mean \pm SD (n=3).



Figure S12. The blood biochemical indexes (ALB, ALT, AST, CRE, UREA) of mice injected with **PSSF** (50 mg/kg, once every other day, 3 times in total).



Figure S13. Cellular uptake of DOX at 2, 4, 8 and 12 h under different treatments (DOX: 2 μ g/mL, p53: 1.85 μ g/mL).



Figure S14. After mice tail vein injection, the blood retention (A) and bio-distribution of DOX@**PSSF** in major organs (B) at various time points.